Variant histologies in bladder cancer are like different genres of music Same stage - different openers and headliners Watch here ➡️ x.com/uromigos/sta...

🎶 Wondering how to tackle variant histologies in bladder cancer? 🎧 Watch here ⬇️ x.com/uromigos/sta... @Uromigos @Dr_Aggen @BladderCancerUS #BladderCancer #UroOnc #GUonc #PathTwitter

If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here! shorturl.at/uTCUA

Very proud of rising star fellow Aditi Gupta for her work on immune profiling in mUC patients receiving EV #ASCOGU @MSKCancerCenter #GU25

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with ORR of 41% DCR 90% 50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor @MSKCancerCenter #ASCOGU #GU25

Excited to hear a review of the DV + PD-1 from our MSK Cancer Center colleague Scot Niglio #ASCOGU #GU25 Path Cr rate of 84.6% in HER2 3+

#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25

Congrats to Vinod Balachandran, a surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, for being named to the inaugural edition of the @washingtonpost's Next 50, a list of up-and-coming changemakers shaping society in 2025. bit.ly/3CMJhN6

Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer www.nature.com/articles/s41... This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab www.nature.com/articles/s41...

An explainer about how health research funding happens and why this NIH funding cycle shutdown matters: www.msnbc.com/opinion/msnb...

Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer

This GU oncology family — wonderful first #AUC3 consensus conference! @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social

At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer

Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session

Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer

Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer

As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...

Surgeon General Calls for Cancer Warnings on Alcohol www.nytimes.com/2025/01/03/h... I think American Cancer Society and @ascocancer.bsky.social @jrgralow.bsky.social should support this initiative @oncoalert.bsky.social

Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer. - NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe

My heart sank when I heard the news that Felix Feng has passed away. Felix was such a gentle and uplifting force for so many of us who work in the same field - and for anyone he touched. Although he has left us, his impact will be felt forever. ow.ly/Uc3H50TSBiC

Rich Matulewicz #SUO24 “Blockbuster New Therapy for Cancer…. Smoking Cessation “. @joshmeeks.bsky.social @yawnyame.bsky.social @wandering-gu.bsky.social

#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis @urotoday

@RichMatulewicz representing @UrologyMSK at the #SUO24 discussing clinical evolution in the management of seminoma.

AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment Some questions remain to be answered related to: ▶️ Heterogeneity of disease ▶️ Interreader variability of pathology assessment ▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social

We are excited to enroll patients with LN + bladder cancer on our neoadjuvant enfortumab vedotin + pembrolizumab trial @mskcc.bsky.sm Now enrolling patients with N1-N3 disease #BLCSM 6 Cycles EV + P -> Cystectomy -> Pembrolizumab www.mskcc.org/cancer-care/...

We are actively enrolling patients with high risk bladder cancer on a trial evaluating a personalized mRNA neoantigen vaccine following bladder surgery. @mskcc.bsky.social #blcsm #bladdercancer www.mskcc.org/cancer-care/...

Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles

As we embark on Thanksgiving week I want to take a moment to reflect on this year and my family. Unfortunately I lost my sister to lung cancer in August. blog.youtube/inside-youtu...